| 591 |
abnormal |
vitamin K metabolic process
(GO:0042373)
|
vitamin K
(CHEBI:28384)
|
1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
|
| 590 |
decreased |
hemostasis
(GO:0007599)
|
|
1133: Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
|
| 589 |
decreased |
|
blood coagulation factors
(MESH:D001779)
|
1133: Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
|
| 588 |
occurrence |
anemia
(MP:0001577)
|
|
1132: Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal
|
| 587 |
abnormal |
cellular detoxification
(GO:1990748)
|
|
1132: Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal
|
| 586 |
decreased |
transport
(GO:0006810)
|
nutrient
(CHEBI:33284)
|
1132: Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal
|
| 585 |
decreased |
carboxylation reaction
(MI:1139)
|
coagulation factor X (mouse)
(PR:O88947)
|
1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
|
| 584 |
decreased |
carboxylation reaction
(MI:1139)
|
coagulation factor IX (mouse)
(PR:P16294)
|
1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
|
| 583 |
decreased |
carboxylation reaction
(MI:1139)
|
coagulation factor VII (mouse)
(PR:P70375)
|
1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
|
| 582 |
decreased |
carboxylation reaction
(MI:1139)
|
prothrombin
(PR:000007299)
|
1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
|
| 581 |
abnormal |
wound healing
(GO:0042060)
|
|
1130: Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
|
| 580 |
abnormal |
hemostasis
(GO:0007599)
|
|
1122: Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis
|
| 579 |
increased |
|
reactive oxygen species
(CHEBI:26523)
|
None
|
| 578 |
abnormal |
role
(MESH:D012380)
|
|
1108: Abnormal, Role change within caste
|
| 577 |
increased |
|
Viral load
(MESH:D019562)
|
1109: Increased, Deformed Wing Virus levels
|
| 576 |
occurrence |
ischemia
(MESH:D007511)
|
kidney
(UBERON:0002113)
|
1105: Occurrence, renal ischemia
|
| 575 |
increased |
|
3,3',5-triiodo-L-thyronine
(CHEBI:18258)
|
1116: Decreased, Triiodothyronine (T3) in tissues
|
| 574 |
increased |
metamorphosis
(GO:0007552)
|
|
1101: Altered, Amphibian metamorphosis
|
| 573 |
increased |
|
mesothelioma
(MESH:D008654)
|
None
|
| 572 |
increased |
cell proliferation
(GO:0008283)
|
mesothelium
(UBERON:0001136)
|
1089: Increased, Cell Proliferation (mesothelium)
|
| 571 |
increased |
cell death
(GO:0008219)
|
pleura
(UBERON:0000977)
|
1086: persistent, cytotoxicity (pleura or peritoneum)
|
| 570 |
increased |
hyperplasia
(MESH:D006965)
|
mammary gland
(UBERON:0001911)
|
1085: Increased, hyperplasia (mammary gland)
|
| 569 |
increased |
prolactin secretion
(GO:0070459)
|
prolactin
(PR:000013246)
|
1084: Increased, prolactin secretion
|
| 568 |
increased |
synaptic transmission, dopaminergic
(GO:0001963)
|
dopaminergic neuron
(CL:0000700)
|
1083: Decreased, Dopaminergic activity
|
| 567 |
increased |
Pituitary adenoma
(HP:0002893)
|
Adenoma
(MESH:D000236)
|
1082: Increased, adenomas (pituitary)
|